AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPsychiatry and PsychologyPhenomena and ProcessesAnthropology, Education, Sociology and Social PhenomenaInformation ScienceNamed GroupsHealth Care
Peripheral Blood Stem Cell TransplantationHematopoietic Stem Cell TransplantationTransplantation, HomologousTransplantation, AutologousBone Marrow TransplantationGraft vs Host DiseaseTransplantation ConditioningHematopoietic Stem Cell MobilizationLeukapheresisGranulocyte Colony-Stimulating FactorTreatment OutcomeHematologic NeoplasmsStem CellsBlood Component RemovalHematopoietic Stem CellsAntigens, CD34Tissue DonorsStem Cell TransplantationImmunosuppressive AgentsGraft SurvivalMelphalanCombined Modality TherapyCyclophosphamideRetrospective StudiesMultiple MyelomaBusulfanAntineoplastic Combined Chemotherapy ProtocolsTime FactorsCord Blood Stem Cell TransplantationSurvival RateRecurrenceSurvival AnalysisBlood DonorsHistocompatibilityBlood CellsHistocompatibility TestingLymphoma, Non-HodgkinCytomegalovirus InfectionsMyeloablative AgonistsFollow-Up StudiesBlood Cell CountTransplantation ChimeraTransplantationEtoposideWhole-Body IrradiationKidney TransplantationAntineoplastic Agents, AlkylatingHeat StrokeProspective StudiesRemission InductionThiotepaMortalityOpportunistic InfectionsLeukemiaHematopoiesisImmunocompromised HostInfectionRisk FactorsCause of DeathSalvage TherapyIncidenceBone Marrow PurgingDisease-Free SurvivalVidarabinePrognosisNeoplasmsAnemia, AplasticHematologic DiseasesIfosfamideHodgkin DiseaseCyclosporinePlatelet CountTransplantsEmbryonic Stem CellsFlow CytometryLeukemia, Myeloid, AcuteCytarabineLeukocytes, MononuclearTransplantation, IsogeneicLeukocyte TransfusionLeukemia, Myelogenous, Chronic, BCR-ABL PositiveCell SeparationLymphocyte DepletionCytomegalovirusPOEMS SyndromeAcute DiseaseAdult Stem CellsFatal OutcomeLymphomaAmyloidosisImmunosuppressionGraft RejectionRecombinant ProteinsImmunophenotypingAge FactorsT-LymphocytesPlatelet TransfusionVincristineFeasibility StudiesBone Marrow
TransplantationHSCTMorbidityProgenitor cellsPatientsHuman leukocyGVHDOutcomesPost-transplantRecipientsInfusionUmbilicalAllogeneic stem cell transBiol Blood Marrow TransplantTotal Body IrradiSevereChemotherapyCentersMesenchymal stemAplastic anemiaAcuteMarrowClinicalRelapseCohortIncidenceRecipient'sNonrelapse mortalityHaploidentical donorsProphylaxisInfectionsHematologicSmearCurativeImmune systemMismatched unrelated donorsTransfusionGraft-versus-tumor2022DifferentiateEmbryonic stemPrevention
Transplantation87
HSCT24
  • Cells for HSCT may be obtained from the patient himself or herself (autologous transplant) or from another person, such as a sibling or unrelated donor (allogeneic transplant) or an identical twin (syngeneic transplant). (medscape.com)
  • An important barrier to HSCT has been the inability to secure a suitable donors. (medscape.com)
  • The National Marrow Donor Program (NMDP), founded in 1986, and the World Marrow Donor Association (WMDA), founded in 1988, were established to (1) locate and secure appropriate unrelated-donor HSCT sources for patients by promoting volunteer donation of bone marrow and peripheral blood stem cells in the community and (2) promote ethical practices of sharing stem cell sources by need, rather than by geographic location of the donor. (medscape.com)
  • Conclusion: Allo-HSCT is safe and effective for HRAA, and haplo-HSCT can be used as a safe and effective alternative for newly diagnosed HRAA patients who cannot obtain HLA-matched sibling donors. (bvsalud.org)
  • Five patients received autologous HSCT: threemarrow and two peripheral blood stem cells. (cancernetwork.com)
  • In this study, we analyzed patient-reported CF and QoL focusing on long-term transplant survivors after 1st allo-HSCT applying a standardized TBI-technique as conditioning regimen. (biomedcentral.com)
  • Immunocompromised patients who have received a hematopoietic stem cell transplant (HSCT) have an incidence of active tuberculosis infection that is 10 to 40 times higher than the general population. (contagionlive.com)
  • In the analysis, the investigators included 200 patients made up of 63 allogeneic-HSCT recipients, 74 autologous-HSCT recipients, and 63 HSCT donors. (contagionlive.com)
  • Further, the HSCT was peripheral blood in 83 patients, bone marrow in 21, and primed-bone marrow in 21 patients. (contagionlive.com)
  • The study found that rates of latent tuberculosis were 17% in all-HSCT recipients, 24% in auto-HSCT, and 39% in donors. (contagionlive.com)
  • Thus, we studied the safety, efficacy, and feasibility of transfer of gene modified donor T-cells shortly after allo-HSCT in two clinical trials between 2002 and 2007 and here we compare the results to unmodified donor leukocyte infusion (DLI). (frontiersin.org)
  • The aim of these trials was to provide patients with the protection of T-cells after T-cell-depleted allo-HSCT in the matched or mismatched donor setting with an option to delete transduced T-cells, if severe aGvHD occurred within the trial period. (frontiersin.org)
  • Despite prophylactic treatment of the patients with immunosuppressive drugs after allo-HSCT, GvHD is still associated with non-relapse mortality (NRM) and contributes around 25% of NRM. (frontiersin.org)
  • In patients having these risk factors, consolidative allo-HSCT after CAR T-cell therapy may prolong LFS. (biomedcentral.com)
  • Allo-HSCT provides optimal clinical benefit in patients with MRD-negative complete remission, typically within three months after CAR T-cell therapy. (biomedcentral.com)
  • Herein, we summarize the clinical data on consolidative allo-HSCT after anti-CD19 CAR T-cell therapy, as well as the potential factors associated with allo-HSCT benefit. (biomedcentral.com)
  • The combination of CAR T-cell therapy and allo-HSCT has been suggested to reduce the relapse rate of leukemia. (biomedcentral.com)
  • The successful application of HSCT for diseases such as leukemia, lymphoma, myeloma, and inherited blood disorders underscored its broad applicability in clinical practice (Snowden et al. (revistadehematologia.org.mx)
  • Unrelated donor α/β T cell- and B cell-depleted HSCT for the treatment of pediatric acute leukemia. (chop.edu)
  • Unrelated donor (URD) hematopoietic stem cell transplant (HSCT) is associated with an increased risk of severe graft-versus-host disease (GVHD). (chop.edu)
  • The allogeneic HSCT was the most frequently performed (57.14%) and the most used source of Hematopoietic progenitor cells (HPC) was the peripheral blood (54.29%) and 5.71% of these patients developed the Graft versus Host Disease (GVHD), of which one was affected by acute GVHD and another by chronic GVHD. (bvsalud.org)
  • The profile of the clinical variables presented by the children and adolescents of this study shows that the most prevalent diagnosis was ALL, the most frequent toxicities were gastrointestinal, cardiac, respiratory and hematological, the most common HSCT was allogeneic peripheral blood and the greatest cause of mortality was sepsis. (bvsalud.org)
  • Opportunistic infections (OIs) are defined as any in- the infusion of hematopoietic stem cells from a donor fections that occur with increased frequency or severity into a patient who has received chemotherapy, which in HSCT patients. (cdc.gov)
  • Method: We aimed to evaluate the temporal trends in HSCT transplant rates in Argentina. (bvsalud.org)
Morbidity8
  • Vaccine recommendations are based on characteristics of the immunobiologic product, scientific knowledge regarding the principles of active and passive immunization, the epidemiology and burden of diseases (i.e., morbidity, mortality, costs of treatment, and loss of productivity), the safety of vaccines, and the cost analysis of preventive measures as judged by public health officials and specialists in clinical and preventive medicine. (cdc.gov)
  • The elevated risk is also accompanied by higher rates of morbidity and mortality. (contagionlive.com)
  • Acute GvHD contributes significantly to non-relapse morbidity and mortality (NRM), thus prevention or control of this severe complication is necessary. (frontiersin.org)
  • 1980). As with many countries embarking on this procedure, there were challenges related to transplant-related morbidity and mortality. (revistadehematologia.org.mx)
  • Notwithstanding the low morbidity of ALF, approximately one and six cases per million individuals annually worldwide, this serious disease will lead to high mortality and resource costs [ 1 , 2 ]. (springer.com)
  • The acute or fulminant form of the disease (aGvHD) is normally observed within the first 10 to 100 days post-transplant, [9] [10] and is a major challenge to transplants owing to associated morbidity and mortality. (wikipedia.org)
  • Hopefully, following the recommendations made in the guidelines will reduce morbidity and mortality from opportunistic infections in hematopoietic stem cell transplant recipients. (cdc.gov)
  • The loss of CD55 and CD59 renders PNH erythrocytes susceptible to intravascular hemolysis, which can lead to thrombosis and to much of the morbidity and mortality of PNH. (medscape.com)
Progenitor cells11
  • The mutation occurs in hematopoetic stem cells capable of self renewal and additional mutations are associated with clonal progression may occur in progenitor cells conferring a self renewal capability. (standardofcare.com)
  • The paradox is that the mutation provides advantage at the stem cell level and progenitor cells, with a disadvantage at the level of hematopoietic precursors. (standardofcare.com)
  • This article contains highlights of "Guidelines for Pre- allogeneic or autologous, depending on the source of venting Opportunistic Infections among Hematopoi- the transplanted hematopoietic progenitor cells. (cdc.gov)
  • Improved methods and pharmaceutical compositions are provided herein for mobilizing hematopoietic progenitor cells from bone marrow into peripheral blood, comprising the administration of an effective amount of an inhibitor of GTPases, such as Rac1 and Rac2 alone or in combination. (justia.com)
  • When stimulated to divide, they give rise to more committed, differentiated daughter cells with less proliferative potential, called "early progenitor" cells. (justia.com)
  • Current treatments to manage the problems that result from prolonged bone marrow suppression include the reinfusion of a patient's own previously harvested hematopoietic stem and progenitor cells. (justia.com)
  • In such procedures, patients undergo successive treatments with cell mobilization agents to cause mobilization of hematopoietic progenitor cells from the bone marrow to the peripheral circulation for harvesting. (justia.com)
  • B lood cell differentiation begins with multipotent hematopoietic progenitor cells (HPCs), which are located in the marrow spaces of the bone. (nationalacademies.org)
  • As the cells reproduce, they commit to a particular task or cell line and become known as committed progenitor cells . (nationalacademies.org)
  • These committed progenitor cells are difficult to discern from the original multipotent cells but can be cultured to form colonies of specific types of blood cells (Guyton and Hall, 2000). (nationalacademies.org)
  • Umbilical cord blood is a rich source of these committed progenitor cells and, presumably, multipotent HPCs (Knudtzon, 1974). (nationalacademies.org)
Patients57
  • Microtransplantation (MST) is an advanced technology to treat malignant hematological diseases and tumors by infusing patients with granulocyte colony-stimulating factor (G-CSF) mobilized human leukocyte antigen (HLA)-mismatched allogeneic peripheral blood stem cells following a reduced-intensity chemotherapy or targeted therapy. (wikipedia.org)
  • Persistent donor microchimerism was successfully detected in all of the 4 female patients. (wikipedia.org)
  • The 6-year LFS and OS were 76.4% and 82.1%, respectively, in patients who received a high dose of donor CD3+ T cells, which were significantly higher than the LFS and OS in patients who received a lower dose of donor CD3+ T cells (49.5% and 55.3%, respectively). (wikipedia.org)
  • Patients were monitored for donor engraftment of myeloid and lymphoid cells, for clinical response by serial imaging, and for immunologic response by in vitro isolation of donor-derived CD8 + CTLs recognizing recipient minor histocompatibility (H) antigens. (aacrjournals.org)
  • Five patients had progressive disease, two patients had stable disease, and one patient experienced a partial response after receiving donor lymphocyte infusions and IFN-α. (aacrjournals.org)
  • Clones from three patients with a partial response or stable disease recognized antigens expressed on renal cell carcinoma tumor cells. (aacrjournals.org)
  • BACKGROUND: Previous studies have verified the dysfunction of mesenchymal stem cells (MSCs) for immunoregulation in acquired aplastic anemia (AA) patients. (bvsalud.org)
  • All patients except two who received reduced intensity had severe mucositis.Reversible veno-occlusive disease of the liver also developed in two patients.There was one death from graft-vs-host disease and no regimen-related mortality.Engraftment was prompt, with a median recovery of absolute neutrophil count to ³ 500/µL of 12 days (range: 11-18 days). (cancernetwork.com)
  • Four patients were alive withno evidence of disease (three matched unrelated donor and one matched relateddonor). (cancernetwork.com)
  • Thus patients with SCD continue to experience early mortality (DeBaun M et al. (nih.gov)
  • 15% of patients with SCD have an HLA-matched sibling donor. (nih.gov)
  • Patients in the first cohort did not receive post-transplant (PT)-cyclophosphamide (Cy) and 3 patients were transplanted. (nih.gov)
  • One of the 3 patients engrafted but lost the graft at 7 months post-transplant. (nih.gov)
  • Based on the three patients losing their grafts, stopping rules were met and the study moved to the 2nd cohort where 1 dose of Cy was given at 50mg/kg on day 3 post-transplant. (nih.gov)
  • Eight patients were transplanted in the 2nd cohort. (nih.gov)
  • CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells from MDS patients against primary MDS and MDSC CD33+ targets. (stembook.org)
  • The primary purpose of this study is to demonstrate the feasibility of sublingual (SL) administration of tacrolimus in blood and marrow transplant (BMT) patients. (mayo.edu)
  • The aim of this study is to measure the differences in quality of life and mood of hematopoietic stem cell transplant (HCT) patients and their caregivers staying at a hospital hospitality house (HHH), such as the Gift of Life Transplant House, the Help in Healing Home, and the Gabriel House of Care versus staying at a hotel/rental apartment or house. (mayo.edu)
  • The primary purpose of this study is to estimate and compare overall survival between the two arms: patients who are Very Likely to find a Matched Unrelated Donor (MUD) versus those who are Very Unlikely to find a MUD. (mayo.edu)
  • Prior to the transplant, all patients were evaluated with tuberculin skin tests and chest x-ray. (contagionlive.com)
  • Donor chimerism was stabilized after transfusion of the transduced cells in all patients treated. (frontiersin.org)
  • Although anti-CD19 chimeric antigen receptor (CAR) T-cell therapy shows good efficacy in patients with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL), it fails to improve long-term leukemia-free survival (LFS). (biomedcentral.com)
  • Recent clinical data indicate that patients with complex karyotypes, adverse genes, and high pre-infusion minimal residual disease (MRD) by flow cytometry in the bone marrow, were at high risk of relapse after CAR T-cell therapy. (biomedcentral.com)
  • Finally, and most importantly, we provide recommendations for the assessment and management of r/r B-ALL patients undergoing anti-CD19 CAR T-cell therapy. (biomedcentral.com)
  • Patients with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) often have clinicopathological characteristics associated with poor prognosis, such as high tumor burden and high-risk gene mutations. (biomedcentral.com)
  • Risk factors for the development of orthostatic hypotension during autologous stem cell transplant in patients with multiple myeloma. (astct.org)
  • This trial confirmed the results of other trials that demonstrated a substantial incidence of symptomatic hypotension in MM patients in the peri-transplant period following ASCT. (astct.org)
  • In a combined analysis of categorical groups, the patients in the high A- ALC group transplanted in CR1 had the best prognosis for OS and PFS and patients in the low A- ALC group transplanted in CR/PR after second-line therapy had the worse prognosis for OS and PFS. (astct.org)
  • Giving patients stem cells from someone else may help to cure many patients with certain immune diseases. (zhihuiya.com)
  • Patients who have a brother or sister that have stem cells that match the patient. (zhihuiya.com)
  • Patients who do not have a matched sibling donor but have a donor that matches in the National Marrow Donor Program. (zhihuiya.com)
  • To prevent the body from getting rid of the donated cells, patients are given sirolimus. (zhihuiya.com)
  • On the day before the BMT, patients in the matched unrelated donor group also receive a low-dose of whole-body radiation. (zhihuiya.com)
  • This will further improve the chances that the patients body will accept the donor cells. (zhihuiya.com)
  • Patients will get the donor stem cells through an intravenous (IV) line that goes into a vein in their body. (zhihuiya.com)
  • Patients will usually stay in the hospital for 30 days after the transplant. (zhihuiya.com)
  • For the first 3 months after the transplant, patients are watched closely. (zhihuiya.com)
  • Patients will continue to be followed periodically for at least 5 years after the transplant. (zhihuiya.com)
  • The study involved targeted mutational analysis of samples obtained before stem cell transplant from 1,514 MDS patients enrolled at the Center for International Blood and Marrow Transplant Research Repository between 2005 and 2014. (ascopost.com)
  • among patients without TP53 mutations, survival was similar among those with therapy-related MDS vs primary MDS (HR = 1.10, P = .37). (ascopost.com)
  • PPM1D mutation vs no mutation was not associated with poorer survival in patients with therapy-related MDS without TP53 mutations (HR = 1.26, P = .39). (ascopost.com)
  • The clinical presentation of patients with aplastic anemia includes signs and symptoms related to the decrease in bone marrow production of hematopoietic cells. (medscape.com)
  • Although the initial reports showed dismal prognosis, recent data suggest that an increased number of patients with solid and hematological malignancies benefit from intensive care support, with dramatically decreased mortality rates. (springeropen.com)
  • Advances in the management of the underlying malignancies and support of organ dysfunctions have led to survival gains in patients with life-threatening complications from the malignancy itself, as well as infectious and toxic adverse effects related to the oncological treatments. (springeropen.com)
  • In this review, we will appraise the prognostic factors and discuss the overall perspective related to the management of critically ill patients with cancer. (springeropen.com)
  • However, their in-hospital mortality rates are not higher compared with critically ill patients with other comorbidities, such as heart failure, liver cirrhosis, or other serious chronic diseases [ 15 ]. (springeropen.com)
  • The 5-year probability of overall survival (OS) after allogeneic HCT was estimated to be 56% (95% confidence interval[CI], 55%- 57%) for patients receiving a transplant while in CR, and 22% (95% CI, 21%-23%) for those who were experiencing active disease. (apbmt.org)
  • For a long time, stem cells have been utilized to renew the immune system for radiation or chemo- therapy treated patients. (bmrat.org)
  • There may be differences in the anti-leukemia effects of haplo-SCT vs. MSDT [ 21 ], so this study investigated both the asso ciation of MRD status with outcomes in haplo-SCT and MDST settings and also possible differences in the transplant outcomes of patients with positive pre-MRD (as determined by MFC) who underwent haplo-SCT versus MDST. (biomedcentral.com)
  • [10] It is less common in younger patients and in those with closer human leukocyte antigens (HLA) matches between donor and the patient. (wikipedia.org)
  • In many cases, successfully mobilization is not effected in the patient and inadequate numbers of hematopoietic stem cells are harvested from these patients using current methods. (justia.com)
  • The mortality and long-term survival of post-allogeneic hematopoietic stem cell transplant patients are improving due to improvements in condition procedures, methods, novel medicines, and supportive care practices. (ajbm.net)
  • Long-term outcome and late effects in patients transplanted with mobilised blood or bone marrow: a randomised trial. (ajbm.net)
  • To reduce expenses, the company will discontinue development of its preclinical NK cell therapy candidates while continuing to enroll patients in the GDA-201 Phase 1 clinical trial. (advfn.com)
  • Our mission is to bring potentially curative therapies to patients," said Abbey Jenkins, President and Chief Executive Officer of Gamida Cell. (advfn.com)
  • Recently presented data continue to support the clinical benefits and safety of omidubicel, which, if approved, may be a valuable new donor source for patients in need of allogeneic stem cell transplant. (advfn.com)
  • Patients with CHS frequently exhibit hypopigmentation, enhanced susceptibility to bruising, recurrent infections, and peripheral neuropathy. (biomedcentral.com)
Human leukocy1
  • Antibodies directed against white blood cell (WBC) human leukocyte antigen (HLA) in otherwise compatible donor blood are one possible cause. (merckmanuals.com)
GVHD15
  • CIBMTR Chronic GVHD Risk Score Predicts Mortality in an Independent Validation Cohort. (stembook.org)
  • Findings from a study show that using abatacept and sirolimus for GVHD prophylaxis following alloHCT for severe aplastic anemia could reduce the incidence of GVHD and transplant-related mortality. (advancedpractitioner.com)
  • Minor histocompatibility antigen differences likely account for GVHD in HLA-identical sibling stem cell transplants. (unboundmedicine.com)
  • Thus, prophylactic transfusion of donor T-cells has been included in many protocols, despite the increased risk for acute GvHD ( Kolb, 2008 ). (frontiersin.org)
  • In this month's Pharmacy SIG Literature Update: Impact of anti-T-lymphocyte globulin dosing on GVHD in MUD SCT, impact of MRD status before alloHCT on outcomes in secondary AML, low-dose post- transplant cyclophosphamide with low-dose antithymocyte globulin for prevention of GVHD in MUD SCT and more. (astct.org)
  • Endpoints of the study were overall survival (OS) progression-free survival (PFS) transplant-related mortality (TRM) engraftment cumulative incidence of illness and GVHD. (bio-cavagnou.info)
  • GvHD is commonly associated with bone marrow transplants and stem cell transplants . (wikipedia.org)
  • The white blood cells present within the transplanted tissue then attack the recipient's body's cells, which leads to GvHD. (wikipedia.org)
  • GvHD occurs when the donor's immune system's white blood cells reject the recipient. (wikipedia.org)
  • GvHD can also occur after a blood transfusion , known as Transfusion-associated graft-versus-host disease or TA-GvHD if the blood products used have not been gamma irradiated or treated with an approved leukocyte reduction system. (wikipedia.org)
  • In contrast to organ/tissue transplant associated GvHD, the incidence of TA-GvHD is increased with HLA matching (first-degree or close relatives). (wikipedia.org)
  • [11] About one-third to one-half of allogeneic transplant recipients will develop acute GvHD. (wikipedia.org)
  • Low-dose post-transplant cyclophosphamide (PTCy) in conjunction with anti-thymocyte globulin (ATG) appears as a potentially effective graft-versus-host disease (GVHD) prevention strategy in haploidentical hematopoietic cell transplant (haplo-HCT). (biomedcentral.com)
  • These results suggested that ATG/PTCy (low-dose) can reduce both acute and chronic GVHD as compared with standard ATG-based prophylaxis using maternal donor or collateral relatives at particular high GVHD risk. (biomedcentral.com)
  • In this prospective trial, results indicated that low-dose PTCy is sufficient to lower acute GVHD in mouse model, partly due to the boosting of fast regulatory T cell (Treg) reconstitution. (biomedcentral.com)
Outcomes5
  • However, in this particular context, outcomes and early and long-term toxicities remain to be determined, as compared to non-transplant procedures. (bvsalud.org)
  • Composite GRFS and CRFS Outcomes After Adult Alternative Donor HCT. (stembook.org)
  • The superior clinical outcomes of allogeneic SCT versus chemotherapy alone as post-remission treatment could be related to the graft-versus-leukemia (GVL) effects of recovered donor T cells. (biomedcentral.com)
  • Currently, there is little information about the effects of MRD on transplant outcomes in haplo-SCT settings. (biomedcentral.com)
  • Report from the Center for International Blood and Marrow Transplant Research (CIBMTR): current uses and outcomes of hematopoietic cell transplants for blood and bone marrow disorders. (ajbm.net)
Post-transplant4
  • Using mice models, Dr. Fitzhugh et al showed for the first time that sirolimus and post-transplant cyclophosphamide work synergistically to induce tolerance (Fitzhugh CD et al. (nih.gov)
  • When stopping rules were again met, the study advanced to the third cohort which included 100mg/kg Cy in divided doses on days 3 and 4 post-transplant. (nih.gov)
  • Allogeneic HCT has been widely used, while autologous HCT, which is still useful, is less prevalent because of concerns around post-transplant relapse, as well as the recently extended application of allogeneic HCT. (apbmt.org)
  • Each participating center is required to register all consecutive HCTs, report core information for registered HCTs as of post-transplant day 100, and report follow-up information annually. (apbmt.org)
Recipients4
  • Among seven allogeneic transplants,three received matched related peripheral blood stem cells and four receivedmatched unrelated marrow (n = 3) or peripheral blood (n = 1) stem cells.Allogeneic recipients received tacrolimus and methotrexate for graft-vs-hostdisease prophylaxis. (cancernetwork.com)
  • In a new study, a team of investigators from Mexico set out to determine the presence and incidence of both latent and active tuberculosis in recipients and donors living in Mexico, a nation where tuberculosis is endemic. (contagionlive.com)
  • With greater experience and analysis of significant numbers of cases, lung transplant recipients are living longer, and follow-up regimens are becoming streamlined. (medscape.com)
  • Whether the alternated microbiota in the gut contribute to the risk of allograft rejection (AR) and pulmonary infection (PI) in the setting of lung transplant recipients (LTRs) remains unexplored. (nature.com)
Infusion4
  • Stem cell infusion is a relatively simple process that is performed at the bedside. (medscape.com)
  • High pre-lymphodepletion lactate dehydrogenase, low pre-lymphodepletion platelet count, absence of fludarabine in lymphodepletion, persistent leukemic sequence by high throughput sequencing in bone marrow after CAR T-cell infusion, and early loss of CAR T cells have also been linked to relapse after CAR T-cell therapy. (biomedcentral.com)
  • An A-ALC cell infusion containing 0.5 x 109 cells/kg was chosen as a cutoff to evaluate for prognosis. (astct.org)
  • After harvesting, the patient is given high dose chemotherapy or radiotherapy and the bone marrow function is reconstituted by infusion of the cells harvested earlier. (justia.com)
Umbilical2
Allogeneic stem cell trans2
  • The purpose of this study is to assess the effect your disease and the treatment of allogeneic stem cell transplant has upon you before and after your treatment process through questionnaires at certain time points. (mayo.edu)
  • The company highlighted positive data, productive regulatory interactions and progress on commercial readiness activities supporting its lead product candidate, omidubicel, an advanced cell therapy candidate for allogeneic stem cell transplant, as it advances toward its May 1, 2023 target Prescription Drug User Fee Act (PDUFA) action date. (advfn.com)
Biol Blood Marrow Transplant1
Total Body Irradi1
  • The study proposes the use of Fludarabine, Busulfan, Anti Thymocyte Globulin Rabbit (ATG) and Total Body Irradiation as a preparative regimen before hematopoietic stem cell transplant from unrelated donor peripheral blood stem cells (PBSC). (mycancergenome.org)
Severe4
  • citation needed] Indications for microtransplantation are as follows: Hematologic Malignancies Tumors Acute myeloid leukemia (AML) chronic-phase chronic myeloid leukemia (CP-CML) Myelodysplastic syndromes (MDS) Intermediate- or high-risk Non-Hodgkin lymphoma High-risk Hodgkin lymphoma Multiplemyeloma (MM) Severe aplastic anemia (SAA) The cells employed are allogeneic peripheral blood stem cells. (wikipedia.org)
  • Hemolysis is most common and most severe when incompatible donor RBCs are hemolyzed by antibodies in the recipient's plasma. (merckmanuals.com)
  • Although advances in tissue typing and cross-match testing have helped to deter severe transplant rejection, rejection may result from direct cellular attack (cellular rejection) or be mediated by antibodies (humoral rejection). (medscape.com)
  • Severe allograft rejection (AR) and pulmonary infection (PI) are the most common complications within 1 year after the transplant. (nature.com)
Chemotherapy5
  • The purpose is to deliver chemotherapy, immunotherapy, and/or radiation to eliminate malignancy, prevent rejection of new stem cells, and create space for the new cells. (medscape.com)
  • The objective of the study is to prepare the patient's body before a stem cell transplant by using an antibody-drug instead of radiation/chemotherapy to make transplants safer. (fanconi.org)
  • In April 1960, Dr. Álvaro Gómez-Leal, presented during the first meeting of the Agrupación Mexicana para el Estudio de la Hematología, A.C., data on a transplant of allogeneic stem cells in a patient with acute leukemia done in Monterrey, Mexico: the patient received high-dose chemotherapy followed by stem cells from the bone marrow of his brother, improving and obtaining remission for months but relapsing and subsequently died. (revistadehematologia.org.mx)
  • They can also be used for increasing white blood cell survival and for chemotherapy. (justia.com)
  • The use of high-dosage chemotherapy or radiotherapy for bone marrow ablation requires subsequent incorporation of hematopoietic stem cells into the patient, in which case prior harvesting of such cells is required. (justia.com)
Centers3
  • A prospective multicenter cohort of LTRs was identified in the four lung transplant centers. (nature.com)
  • Commercial readiness activities have made progress as the company prepares to onboard approximately 10-15 of the top 70 transplant centers in the United States in 2023. (advfn.com)
  • Omidubicel has received positive feedback from leading transplant centers, including ones that did not participate in the company's clinical trials. (advfn.com)
Mesenchymal stem1
  • mesenchymal stem cells are most commonly used because they are easy to obtain and present no ethical problems. (springer.com)
Aplastic anemia1
  • Aplastic anemia is a syndrome of bone marrow failure characterized by peripheral pancytopenia and marrow hypoplasia (see the image below). (medscape.com)
Acute8
  • The secondary objectives are to evaluate the relapse-free and overall survival after hematopoietic stem cell transplant as well as to evaluate the incidence of acute and chronic graft-versus-host disease after this preparative regimen. (mycancergenome.org)
  • increased risk of myelodysplastic syndrome (MDS), acute myeloid leukaemia (AML) and T-cell acute lymphoblastic leukaemia (T-ALL). (eviq.org.au)
  • A heterogenous group of myeloid disorders characterized by somatically mutated hematopoietic stem cells,the presence of variable peripheral cytopenias, and a broad risk of progression to acute myeloid leukemia (AML). (standardofcare.com)
  • Acute liver failure is a life-threatening clinical syndrome characterized by rapid development of hepatocellular necrosis leading to high mortality and resource costs. (springer.com)
  • In recent years, a growing number of studies have shown that stem cells can effectively treat acute liver failure. (springer.com)
  • Allergic reactions The most common complications of transfusion are Febrile nonhemolytic reactions Chill-rigor reactions The most serious complications, which have very high mortality rates, are Acute hemolytic. (merckmanuals.com)
  • Acute Kidney Injury (AKI) Acute kidney injury is a rapid decrease in renal function over days to weeks, causing an accumulation of nitrogenous products in the blood (azotemia) with or without reduction in amount of urine. (merckmanuals.com)
  • Peripheral blood grafts from unrelated donors are associated with increased acute and chronic graft-versus-host disease without improved survival. (ajbm.net)
Marrow32
  • The stem cells are collected from donor's blood through a process known as apheresis after a certain period of daily subcutaneous injections of Granulocyte-colony stimulating factor, serving to mobilize stem cells from the donor's bone marrow into the peripheral circulation. (wikipedia.org)
  • Eligibility includes having developed cytopenias (reduced blood cell counts) and not having an HLA-identical matched sibling donor for bone marrow transplant (BMT). (fanconi.org)
  • Late-occurring Venous Thromboembolism in Allogeneic Blood or Marrow Transplant Survivors - a BMTSS-HiGHS2 Risk Model. (stembook.org)
  • Peripheral Blood versus Bone Marrow from Unrelated Donors: Bone Marrow allografts have improved Long-term Overall and Graft-versus-Host Disease, Relapse-Free Survival. (stembook.org)
  • Instruments included the Functional Assessment of Cancer Therapy-Bone marrow transplant (FACT-BMT, version 4), the FACT-Cognition Function (FACT-Cog, version 3) and the Patient Health Questionaire-4 (PHQ-4). (biomedcentral.com)
  • Source of stem cells were peripheral blood, bone marrow or cord blood. (biomedcentral.com)
  • Criteria for diagnosis of MDS consist of anemia, thrombocytopenia, or neutropenia that persist for six months or longer, dysplasia greater than 10% in at least one bone marrow cell lineage, and MDS associated clonal cytogenetic abnormalities or molecular markers. (standardofcare.com)
  • When the bone marrow hematopoietic cells are mostly clonally derived cells, the disease is clinically manifested as cytopenia and morphologic dysplasia. (standardofcare.com)
  • The immune system cells come from the bone marrow where they grow from special cells called stem cells. (zhihuiya.com)
  • This lets the cells of the donor go into the bone marrow and produce normal immune cells. (zhihuiya.com)
  • The cells make their way to the bone marrow space and slowly refill the marrow over the next several weeks. (zhihuiya.com)
  • At day 100 after the transplant a sample of bone marrow is taken. (zhihuiya.com)
  • In the mid-20th century, Dr. E. Donnall Thomas achieved a landmark breakthrough by successfully performing the first bone marrow transplant between identical twins in 1956 (Thomas et al. (revistadehematologia.org.mx)
  • It was only until 1988 when the same group could report on their first successful bone marrow transplant (León-Rodríguez et al. (revistadehematologia.org.mx)
  • Low-power view of hematoxylin-eosin-stained bone marrow showing hypocellularity, with increased adipose tissue and decreased hematopoietic cells in the marrow space. (medscape.com)
  • The theoretical basis for marrow failure includes primary defects in or damage to the stem cell or the marrow microenvironment. (medscape.com)
  • External insults (eg, infections, radiation, drugs) may disrupt stem cell homeostasis in marrow environment, leading to altered growth. (medscape.com)
  • The number of related HCTs has remained stable, while the use of peripheral blood stem cells (PBSCs) has now largely replaced that of bone marrow (BM). (apbmt.org)
  • Adult stem cells were firstly isolated from bone marrow in mice (Spangrude, Heimfeld, and Weissman, 1988) and later in humans. (bmrat.org)
  • The present invention relates generally to improved methods and pharmaceutical compositions for mobilizing hematopoietic stem and progenitor cell from bone marrow into peripheral blood by administration of at least one inhibitor of a GTPase, such as Rac1 and/or Rac2 GTPase. (justia.com)
  • Stem cells represent a very small percentage of bone marrow cells, and are normally quiescent. (justia.com)
  • These therapies decrease a patient's white blood cell counts, suppress bone marrow hematopoietic activity, and increase the patient's risk of infection and/or hemorrhage. (justia.com)
  • The success of treatment crucially depends on the mobilization of the bone marrow stem cells, the subsequent return of which permits the patient to achieve reconstitution of a functioning hematopoietic system. (justia.com)
  • Low power, H and E showing a hypocellular bone marrow with increased adipose tissue and decreased hematopoietic cells in the marrow space. (medscape.com)
  • a broad range of disorders for which transplantion of HPCs from an adult donor is also successful, including hematological malignancies, solid tumors, constitutional and acquired bone marrow failure syndromes, hemoglobinopathies, congenital immune deficiencies, and inherited disorders of metabolism (Gluckman et al. (nationalacademies.org)
  • Bone marrow is the place for the production of the hematopoietic cells which differentiate in to three groups: red blood cells, white blood cells and platelets. (longdom.org)
  • Hematopoietic stem cells (HSCs) are very rare cells, representing approximately one in 100,000 bone marrow (BM) cells in the adult. (longdom.org)
  • Chronic lymphocytic leukemia ( CLL ) is a type of cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell ). (wikipedia.org)
  • [4] [9] CLL results in the buildup of B cell lymphocytes in the bone marrow, lymph nodes, and blood . (wikipedia.org)
  • [17] Less commonly, the disease comes to light only after the cancerous cells overwhelm the bone marrow, resulting in low red blood cells, neutrophils, or platelets. (wikipedia.org)
  • [18] Whereas, with CLL, diseased cells propagate from within the bone marrow, in SLL they propagate from within the lymphatic tissue. (wikipedia.org)
  • The principal studies used to establish the diagnosis of PNH are flow cytometry of peripheral blood and bone marrow analysis. (medscape.com)
Clinical10
  • Each of those cell sources has specific advantages and disadvantages, and each has found particular clinical applications. (medscape.com)
  • Collaborative molecular research projects will focus on the analysis of clinical biological materials collected from the study to develop an understanding of the natural history of squamous cell cancers in individuals with FA. (fanconi.org)
  • The second presentation was by Dr. Courtney Fitzhugh, M.D , Lasker Clinical Research Scholar, Laboratory of Early Sickle Mortality Prevention on the NIH Experience in Nonmyeloablative Allogeneic Transplant for SCD. (nih.gov)
  • The care of an individual who has developed a related tumour or cancer should be individualised based on their clinical situation, their family history and the monitoring they need as part of their treatment and post-treatment follow-up. (eviq.org.au)
  • The onset is insidious, and the initial clinical manifestation is frequently related to anemia or bleeding, although fever or infections may be noted at presentation. (medscape.com)
  • Scientists working in basic, translational, and clinical cancer metabolism research are invited to join the Academy in New York on April 17th to discuss the intersection between cell signaling and metabolism. (nyas.org)
  • We performed a systematic review and meta-analysis to assess mortality post allo-HCT through a comprehensive literature search using PUBMED/MEDLINE, CINAHL, Web of Science, and EMBASE up to April 30, 2023 and extracted clinical outcome data relating to benefits followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. (ajbm.net)
  • Especially since our engineered NK cell therapy candidates, which are derived from healthy donors, have demonstrated encouraging pre-clinical data that differentiate them from other NK cell therapy approaches. (advfn.com)
  • Clinical manifestations of PNH occur when a HSC clone carrying somatic PIGA mutations acquires a growth advantage and differentiates, generating mature blood cells that are deficient of GPI-anchored proteins. (medscape.com)
  • The name of the disorder is a descriptive term for the clinical consequence of red blood cell (RBC) breakdown with release of hemoglobin into the urine, which manifests most prominently as dark-colored urine in the morning (see image below). (medscape.com)
Relapse4
  • Follistatin and Soluble Endoglin Predict 1-year Non-Relapse Mortality after Allogeneic Hematopoietic Cell Transplant. (stembook.org)
  • CD34-selection of stem cells reduces the risk of aGvHD, but also leads to increased infectious complications and relapse. (frontiersin.org)
  • Early loss or exhaustion of CAR T cells, selection of CD19-negative clones, downregulation of CD19 expression, lineage switch of leukemia, and tumor microenvironment are important factors contributing to relapse after CAR T-cell therapy [ 9 , 10 ]. (biomedcentral.com)
  • RAS pathway mutations were associated with an increased risk of relapse with reduced-intensity conditioning, and JAK2 mutations were associated with an increased risk of nonrelapse mortality. (ascopost.com)
Cohort1
  • Both study cohort and control are transplanted from maternal donor or collateral relatives. (biomedcentral.com)
Incidence1
Recipient's2
  • Donor's stem cells, which have been processed, will also accelerate functional recovery of recipient's hematopoietic stem cells, greatly reducing infections and transplant-related mortality. (wikipedia.org)
  • Mislabeling the recipient's pretransfusion sample at collection and failing to match the intended recipient with the blood product immediately before transfusion are the usual causes. (merckmanuals.com)
Nonrelapse mortality1
Haploidentical donors2
  • Transduced cells were transfused either after day +60 (matched donors) or on day +42 (haploidentical donors). (frontiersin.org)
  • Outcome data with TCRαβ/CD19 depletion generally describe haploidentical donors, with relatively few URDs. (chop.edu)
Prophylaxis2
  • Issues with T-cell depletion or prophylaxis consisted of trimethoprim-sulfamethoxazole or pentamidine if hematopoiesis was jeopardized. (bio-cavagnou.info)
  • Individuals received no cytomegalovirus (CMV) specific prophylaxis with ganciclovir or valganciclovir but CMV seronegative individuals received seronegative blood products regardless of the donor's serologic status. (bio-cavagnou.info)
Infections2
  • Mild or moderate infections and positive blood cultures with thought to be a contaminant were excluded. (bio-cavagnou.info)
  • Although rare, pulmonary embolism, infections, or neoplasms in the allograft may be diagnosed in this manner, which would affect the decision to use the donor lung. (medscape.com)
Hematologic2
  • [ 1 ] More than half of autologous transplantations are performed for multiple myeloma and non-Hodgkin lymphoma , and the vast majority of allogeneic transplants are performed for hematologic and lymphoid cancers. (medscape.com)
  • Statistical Analysis This study was designed as a single center non-randomized phase II trial to investigate the feasibility and security of a non-myeloablative conditioning routine plus an unmodified peripheral blood stem cell transplant in individuals with hematologic malignancies who are not candidates for myeloablative conditioning by virtue of age prior organ toxicity or intensity of prior therapy. (bio-cavagnou.info)
Smear1
  • Diagnosis of this neoplasm is usually incidental (85% are asymptomatic when diagnosed) when the patient has a CBC and/or peripheral blood smear . (cancer.gov)
Curative1
  • The first step was to provide a curative option for the majority of adults with SCD that are not eligible for the standard transplant because of age and co-morbidities including heart, lung, and kidney disease. (nih.gov)
Immune system3
  • 1957). This pioneering work laid the foundation for the exploration of hematopoietic stem cells and their role in treating diseases of the blood and immune system. (revistadehematologia.org.mx)
  • White blood cells of the donor's immune system which remain within the donated tissue (the graft) recognize the recipient (the host) as foreign (non-self). (wikipedia.org)
  • HSCs are characterized by their unique ability to self-renew and give rise to the entirety of the blood and immune system throughout the lifetime of an individual. (longdom.org)
Mismatched unrelated donors1
Transfusion4
  • Early recognition of symptoms suggestive of a transfusion reaction and prompt reporting to the blood bank are essential. (merckmanuals.com)
  • Further transfusion should be delayed until the cause of the reaction is known, unless the need is urgent, in which case type O Rh-negative red blood cells (RBCs) should be used. (merckmanuals.com)
  • ABO and Rh typing There has been a gradual decrease in overall transfusion due to patient blood management programs. (merckmanuals.com)
  • Treatment of thrombopathy requires, first of all symptomatic measures: haemostatic glues, desmopressin and the blood transfusion which must be only reserved for the difficult gestures or for the high hemorrhagic risk. (longdom.org)
Graft-versus-tumor1
  • CD8 + CTL-recognizing minor H antigens on tumor cells can be isolated posttransplant and could contribute to the graft- versus -tumor effect. (aacrjournals.org)
20223
  • Blood Adv. 2022. (stembook.org)
  • Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today provided a business update and reported financial results for the year ended December 31, 2022. (advfn.com)
  • As of December 31, 2022, Gamida Cell had total cash and cash equivalents of $64.7 million. (advfn.com)
Differentiate5
  • Chronic myelogenous leukemia (CML), also known as chronic myeloid leukemia, is a myeloproliferative disorder characterized by increased proliferation of the granulocytic cell line without the loss of their capacity to differentiate. (medscape.com)
  • 1992). Since then, hematopoietic stem cells, with their unique ability to differentiate into various blood cell types, have proven to be a revolutionary tool in the treatment of numerous hematological disorders. (revistadehematologia.org.mx)
  • MSCs have the capacity of multiple differentiations and self-renewal and have been proven to be able to differentiate into a series of cell lineages, such as adipocytes, osteoblasts, chondroblasts, and hepatocyte-like cells (HLCs). (springer.com)
  • Our bodies contain a pool of stem cells that have the ability to differentiate into any other cell type in the body. (bmrat.org)
  • Stem cells are widely defined by two main characteristics: the ability to self-renew (divide in a way that reproduces more identical stem cells) and to differentiate (to turn stem cells into specialized cells that form different organs and tissues). (bmrat.org)
Embryonic stem5
Prevention1
  • Societal benefits include creation and maintenance of herd immunity against communicable diseases, prevention of disease outbreaks, and reduction in health-care--related costs. (cdc.gov)